Skip to main content
Disciplines
Automotive Business IT + Informatics Construction + Real Estate Electrical Engineering + Electronics Energy + Sustainability Insurance + Risk Finance + Banking Management + Leadership Marketing + Sales Mechanical Engineering + Materials
Events
DE
EN
Books
Journals
Topic Page
Marketing
Start single access now
Access for companies
EXTENDED SEARCH
Log in
Top
Published in:
Different Shades of Fungal Metabolites: An Overview Read chapter Read first chapter

2017 | OriginalPaper | Chapter

24. Production of Cyclosporine A by Submerged Fermentation

Authors : Tehmina Anjum, Wajiha Iram

Published in: Fungal Metabolites

Publisher: Springer International Publishing

Log in

Activate our intelligent search to find suitable subject content or patents.

search-config
loading …

Abstract

Cyclosporin A is a cyclic undecapeptide with a variety of biological activities including immunosuppressive, anti-inflammatory, antifungal, and antiparasitic properties. It is an extremely powerful immunosuppressant and is approved for the use in organ transplantation to prevent graft rejection in kidney, liver, heart, lung, and combined heart–lung transplants. As its role in transplantation surgery increases, the demand on industry for improved yields intensifies. For this reason, this chapter mainly focuses on enhanced production of cyclosporin A from microbes by different techniques.

Dont have a licence yet? Then find out more about our products and how to get one now:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

  • über 102.000 Bücher
  • über 537 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Maschinenbau + Werkstoffe
  • Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

inform now

Springer Professional "Technik"

Online-Abonnement

Mit Springer Professional "Technik" erhalten Sie Zugriff auf:

  • über 67.000 Bücher
  • über 390 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Maschinenbau + Werkstoffe




 

Jetzt Wissensvorsprung sichern!

inform now
previous chapter Cordycepin: A Cordyceps Metabolite with Promising Therapeutic Potential
next chapter Streptokinase Production in Yeast Systems
Literature
1.
Kock JLF, Strauss T, Pohl CH, Smith DP, Botes PJ, Pretorius EE, Tepeny T, Sebolai O, Botha A, Nigam S (2001) Bioprospecting for novel oxylipins in fungi: the presence of 3-hydroxy oxylipins in Pilobolus. Antonie Van Leeuwenhoek 80:93–99CrossRef
2.
Bode HB, Bethe B, Hofs R, Zeek A (2002) Big effects from small changes: possible ways to explore nature’s chemical diversity. Chembiochem 3:619–627CrossRef
3.
Donadio S, Monicardini P, Alduina R, Mazzaa P, Chiocchini C, Cavaletti L, Sosio M, Puglia AM (2002) Microbial technologies for the discovery of novel bioactive metabolites. J Biotechnol 99:187–198CrossRef
4.
Chin YW, Balunas MJ, Chai HB, Kinghorn AD (2006) Drug discovery from natural sources. AAPS J 8:239–253CrossRef
5.
Gunatilaka AAL (2006) Natural products from plant-associated microorganisms: distribution, structural diversity, bioactivity, and implications of their occurrence. J Nat Prod 69:509–526CrossRef
6.
Mitchell AM, Strobel GA, Hess WM, Vargas PN, Ezra D (2008) Muscodor crispans, a novel endophyte from Anans ananassoides in the Bolivian Amazon. Fungal Divers 31:37–43
7.
Stadler M, Keller NP (2008) Paradigm shifts in fungal secondary metabolite research. Mycol Res 112:127–130CrossRef
8.
9.
Demain AL (2000) Small bugs, big business: the economic power of the microbe. Biotechnol Adv 18:499–514CrossRef
10.
Latge JP (1999) Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev 12:310–350
11.
Vinokurova NG, Khmel NI, Baskunov BP, Arinbasarov MU (2003) Analysis of secondary metabolites of microscopic fungi of the genus Penicillium by chromatographic techniques. Appl Biochem Microbiol 39:192–196CrossRef
12.
Ward OP, Qin MW, Dhanjoon J, Ye J, Singh A (2006) Physiology and biotechnology of Aspergillus. Adv Appl Microbiol 58:1–75CrossRef
13.
Budavari SM, Neal JO, Smith A, Heckelman PE (1996) The Merck index: an encyclopedia of chemicals, drugs and biologicals, 12th edn. Merck & Company, Whitehouse Station, p 1498
14.
Kobei H, Traber R (1982) Directed biosynthesis of cyclosporins. Eur J Appl Microbiol Biotechnol 14:237–240CrossRef
15.
Dreyfuss M, Ham E, Hofmann H (1976) Cyclosporin A and C. New metabolites from Trichoderma polysporum. Eur J Appl Microbiol 3:125CrossRef
16.
Starzl TE, Klintmalm GB, Porter KA, Iwatsuki S, Schroter GP (1981) Liver transplantation with use of cyclosporin A and prednisone. N Engl J Med 305:266–269CrossRef
17.
Lichtiger S, Present DH, Kornbluth A (1994) Cyclosporin in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 26:1841–1845CrossRef
18.
IARC (1990) Pharmaceutical drugs. IARC monographs on the evaluation of carcinogenic risk of chemicals to humans, vol 50. International Agency for Research on Cancer, Lyon, p 415
19.
20.
21.
Wenger RM (1982) Cyclosporin A. Biomed J 3:19–31
22.
Wenger RM (2003) Synthesis of cyclosporin and analogues: structural requirement for immunosuppressive activity. Inter Sympos Cyclosporin 77–85
23.
Wenger RM (1986) Synthesis of cyclosporin and analogues: structural requirements for immunosuppressive activity. Prog Allergy 38:46–64
24.
Velkov T, Singaretnam GL, Lawen A (2006) An improved purification procedure for cyclosporin synthetase. Protein Expr Purif 45:275–287CrossRef
25.
Braun W, Kallen J, Milkol V, Walkinshaw MD, Wuthrich K (1995) Three dimensional structure and actions of immunosuppressants and their immunophilins. FASEB J 9:63–70
26.
Sigler GF, Ghoshal M, Rashid S (2008) Homogeneous double receptor agglutination assay for immunosuppressant drugs. Patent Cooperation Treaty, pp 1–22
27.
Penkler LJ, Muller RH, Runge SA, Ravelli V (2003) Pharmaceutical cyclosporin formulation with improved biopharmaceutical properties, improved physical quality and greater stability, and method for producing said formulation. US Patent 6,551,619. Pharmatec International S.R.L
28.
Ismailos G, Peppas C, Dressman J, Macheras P (1991) Unusual solubility behavior of cyclosporin ‘A’ in aqueous media. J Pharm Pharmacol 43:287–289CrossRef
29.
Sullivan PG, Thompson M, Scheff SW (2000) Continuous infusion of cyclosporin A postinjury significantly ameliorates cortical damage following traumatic brain injury. Exp Neurol 161(2):31–37CrossRef
30.
National Toxicology Program (2005) Cyclosporin A. CAS No. 59865-13-3. National Institute of Environmental Health Sciences. 11th Ed Report on Carcin
31.
MICROMEDEX Thomson Health Care (2001) USPDI-Drug information for the health care professional, vol 1, 21st edn. MICROMEDEX Thomson Health Care, Englewood
32.
Ryffel B, Mihatsch MJ, Fisher GL (1992) Immunosuppression and cancer: the cyclosporin case. Drug Chem Toxicol 15:95–115CrossRef
33.
Novartis. Neoral ® Package insert (2003) Novartis international. Basel. Novartis Pharmaceuticals Corporation, East Hanover, New Jersey
34.
NIOSH Alert (2004) Preventing occupational exposures to antineoplastic and other hazardous drugs in health care settings. National Institute of Occupational Safety and Health. NIOSH-Publications Disseminations, Cincinnati
35.
36.
Gaston RS (2001) Maintenance immunosuppression in the renal transplant recipient: an overview. Am J Kidney Dis 38(6):25–35CrossRef
37.
Lawen A (1996) Biosynthesis and mechanism of action of cyclosporins. Prog Med Chem 33:53–97CrossRef
38.
Velkov T, Lawen A (2003) Non-ribosomal peptide synthetases as technological platforms for the biosynthesis of highly modified peptide bioeffectors – cyclosporin synthetase as a complex example. In: El-Gewely MR (ed) Biotechnology annual review, vol 9. Elsevier Science B.V., The Netherlands. pp 151–197
39.
Riley MR, Hebel KE et al (2000) Drug facts and comparisons. Wolters Kluwer, St. Louis; KU-5, KU-52:1553–1558
40.
Tichelli A, Socie G et al (1999) Effectiveness of immunosuppressive therapy in older patients with aplastic anemia. Ann Intern Med 130:193–201CrossRef
41.
Johns TE, Harbilas JW (1999) Drug-induced hematologic disorders. In: Dipiro JT, Talbert RL et al (eds) Pharmacotherapy: a pathophysiologic approach, 4th edn. Appleton & Lange, Stamford, pp 1584–1587
42.
Frickhofen N, Kaltwasser JP et al (1991) Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporin. The German Aplastic Anemia Study Group. N Engl J Med 324:1297–1304CrossRef
43.
McDonald JW, Feagan BG, Jewell D, Brynskov J, Stange EF, Macdonald JK (2005) Cyclosporin for induction of remission in Crohn’s disease. Cochrane Database Syst Rev 18(2):297
44.
Ozbay A, Karamperis N, Jorgensen KA (2007) A review of the immunosuppressive activity of cyclosporine metabolites: new insights into an old issue. Curr Clin Pharmacol 2:244–248CrossRef
45.
Maurer G (1985) Metabolism of cyclosporine. Transplant Proc 17:19–26
46.
Bertault‐Peres P, Bonfils C, Fabre G et al (1987) Metabolism of cyclosporin A. II. Implication of the macrolide antibiotic inducible cytochrome P‐450 3c from rabbit liver microsomes. Drug Metab Dispos 15:391–398
47.
Kronbach T, Fischer V, Meyer UA (1988) Cyclosporine metabolism in human liver: identification of a cytochrome P‐450III gene family as the major cyclosporine‐metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther 43:630–635CrossRef
48.
Goldberg H, Ling V, Wong PY, Skorecki K (1988) Reduced cyclosporin accumulation in multidrugresistant cells. Biochem Biophys Res Commun 152:552–558CrossRef
49.
Fromm MF (2004) Importance of P‐glycoprotein at blood‐tissue barriers. Trends Pharmacol Sci 25:423–429CrossRef
50.
Watkins PB (1997) The barrier function of CYP3A4 and P‐glycoprotein in the small bowel. Adv Drug Deliv Rev 27:161–170CrossRef
51.
Zhang Y, Benet LZ (2001) The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P‐glycoprotein. Clin Pharmacokinet 40:159–168CrossRef
52.
Freeman DJ (1991) Pharmacology and pharmacokinetics of cyclosporine. Clin Biochem 24:9–14CrossRef
53.
Kahan BD (1986) Individualisation of cyclosporine therapy using pharma cokinetic and pharmacodynamic parameter. Transplantation 40:457–476CrossRef
54.
Fahr A (1993) Cyclosporin clinical pharmacokinetics. Clin Pharmacokinet 24:472–495CrossRef
55.
Baraldo M, Furlanut M (2006) Chronopharmacokinetics of ciclosporin and tacrolimus. Clin Pharmacokinet 45:775–788CrossRef
56.
Heifets M, Cooney GF, Shaw LM, Libetti G (1995) Diurnal variation of cyclosporine clearance in stable renal transplant recipients receiving continuous infusion. Transplantation 60:1615–1617
57.
Curtis JJ, Jones P, Barbeito R (2006) Large within‐day variation in cyclosporine absorption: circadian variation or food effect? Clin J Am Soc Nephrol 1:462–466CrossRef
58.
Ruggeri A Jr, Montebugnoli L, Matteucci A, Zini N, Solimando L, Servidio D, Suppa P, Cadenaro M, Cocco L, Breschi L (2005) Cyclosporin ‘A’ specifically affects nuclear PLCβ1 in immunodepressed heart transplant patients with gingival overgrowth. J Dent Res 84(8):747–751CrossRef
59.
60.
Hiestand PC, Gunn H, Gale J (1985) The immunosuppressive profile of a new natural cyclosporin analogue: Nva2-cyclosporine. Transplant Proc 17:1362–1364
61.
Gregory CR, Kyles AE, Bernsteen L, Wagner GS, Tarantal AF, Christe KL, Brignolo L, Spinner AG, Griffey SM, Paniagua RT, Hubble RW, Borie DC, Morris RE (2004) Compared with cyclosporin, ISATX247 significantly prolongs renal allograft survival in a nonhuman primate model. Transplantation 78:681–685CrossRef
62.
Hiestand PC, Graber M, Hurtenbach V, Hermann P, Borel JF (1992) The new cyclosporin derivative, SDZ IMM 125: in vitro and in vivo pharmacological effects. Transplant Proc 24:31–38
63.
Molino BF, Yang Z (2006) Novel cyclosporin analogues and their pharmaceutical uses. Amr Technology, GOLDMAN Michael L, WO/2006/039164
64.
Rodriguez MA, Cabrera G, Godeas A (2006) Cyclosporin A from a nonpathogenic Fusarium oxysporum suppressing Sclerotinia sclerotiorum. J Appl Microbiol 100(3):575–586CrossRef
65.
66.
Hershey JWB (1991) Translational control in mammalian cells. Annu Rev Biochem 60:717–755CrossRef
67.
Merrick WC (1992) Mechanism and regulation of eukaryotic protein synthesis. Microbiol Rev 56(2):291–315
68.
Kozak M (1992) Regulation of translation in eukaryotic systems. Annu Rev Cell Biol 8:197–225CrossRef
69.
Zocher R, Nihira T, Paul E, Madry N, Peeters H, Kleinkauf H, Keller U (1986) Biosynthesis of cyclosporin ‘A’: partial purification and properties of a multifunctional enzyme from Tolypocladium inflatum. Biochemistry 25(3):550–553CrossRef
70.
Billich A, Zocher R (1987) Enzymatic synthesis of cyclosporin ‘A’. J Biol Chem 262:17258–17259
71.
Lawen A, Traber R, Geyl D, Zocher R, Kleinkauf H (1989) Cell-free biosynthesis of new cyclosporins. J Antibiot 42:1283–1289CrossRef
72.
Lawen A, Traber R, Reuille R, Ponelle M (1994) In vitro biosynthesis of ring-extended cyclosporins. Biochem J 300:395–399CrossRef
73.
Kleinkauf H, Von Dohren H (1988) Research on nonribosomal systems: biosynthesis of peptide antibiotics. In: Kleinkauf H, Von Dohren H, Jaenicke L (eds) The roots of modern biochemistry. de Gruyter Co, Berlin, pp 355–367CrossRef
74.
Lawen A, Zocher R (1990) Cyclosporin synthetase. The most complex peptide synthesizing multienzyme polypeptide so far described. J Biol Chem 265(19):11355–11360
75.
Weber BH, Vogt G, Pruett RC, Stöhr H, Felbor U (1994) Mutations in the tissue inhibitor of metalloproteinases-3 (TIMP3) in patients with Sorsby’s fundus dystrophy. Nat Genet 8(4):352–356CrossRef
76.
Marahiel MA, Stachelhaus T, Mootz HD (1997) Modular peptide synthetases involved in nonribosomal peptide synthesis. Chem Rev 97:2651–2673CrossRef
77.
Hoppert M, Gentzsch C, Schorgendorfer K (2001) Structure and localization of cyclosporin synthetase, the key enzyme of cyclosporin biosynthesis in Tolypocladium inflatum. Arch Microbiol 176:285–293CrossRef
78.
Kurnsteiner H, Zinner M, Kock U (2013) Immunosuppressants. In: Osiewacz H (ed) Industrial applications. Springer- Verlag Berlin Heidelberg, New York. pp 129–156
79.
Sallam LAR, El-Refai AH, Hamdi AA, El-Minofi AH, Abd-Elsalam SI (2003) Role of some fermentation parameters on cyclosporin A production by a new isolate of A. terreus. J Gen Appl Microbiol 49:321–328CrossRef
80.
Metz B, Kossen NW (1977) The growth of molds in the form of pellets. Biotechnol Bioeng 19:781–799CrossRef
81.
Metz B, Kossen NWF, van Suijdam JC (1979) The rheology of mold suspensions. Adv Biochem Eng 11:103–156
82.
Van Suijdam JC, Metz B (1981) Influence of engineering variables upon the morphology of filamentous molds. Biotechnol Bioeng 23:111–148CrossRef
83.
Fattah AYR, El-Enshasy H, Anwar M, Omar H, Abolmagd E, Zahrar AR (2007) Application of factorial experimental designs for optimization of cyclosporin A production by Tolypocladium inflatum in submerged culture. J Microbiol Biotechnol 17:1930–1936
84.
El-Enshasy H, Fattah AY, Atta A, Anwar M, Omar H, El-Magg AS, Zahra AR (2008) Kinetics of cell growth and cyclosporin A production by Tolypocladium inflatum when scaling up from shake flask to bioreactor. J Microbiol Biotechnol 18:128–134
85.
Aarino TH, Agathos SN (1990) Pigmented variants of Tolypocladium inflatum in relation to cyclosporin A production. Appl Microbiol Biotechnol 33:435–437
86.
Chun GT, Agathos SN (1989) Immobilization of Tolypocladium inflatum spores into porous celite beads for cyclosporin ‘A’ production. J Biotechnol 9:237–254CrossRef
87.
Sekar C, Rajasekar VW, Balaraman K (1997) Production of cyclosporin ‘A’ by solid state fermentation. Bioprocess Eng 17:257–259CrossRef
88.
Sekar C, Balaraman K (1998) Optimization studies on the production of cyclosporin A by solid state fermentation. Bioprocess Eng 18:293–296CrossRef
89.
Manpreet S, Sawraj S, Sachin D, Pankaj S, Banerjee UC (2005) Influence of process parameters on the production of metabolites in solid-state fermentation. Malays J Microbiol 1(2):1–9
90.
Agathos SN, Marshall JW, Moraiti C, Parekh R, Madhosingh C (1986) Physiological and genetic factors for process development of cyclosporine fermentations. J Ind Microbiol 1:39–48CrossRef
91.
Lee J, Agathos SN (1989) Effect of amino acids on the production of cyclosporin ‘A’ by Tolypocladium inflatum. Biotechnol Lett 11(2):77–82CrossRef
92.
93.
Margaritis A, Chahal PS (1989) Development of a fructose based medium for biosynthesis of cyclosporin ‘A’ by Beauveria nivea. Biotechnol Lett 11(11):765–768CrossRef
94.
Isaac CE, Jones A, Pickard MA (1990) Production of cyclosporins by Tolypocladium niveum strains. Antimicrob Agents Chemother 34(1):121–127CrossRef
95.
Lee J, Agathos SN (1991) Dynamic of l-valine in relation to the production of cyclosporin ‘A’ by Tolypocladium inflatum. Appl Microbiol Biotechnol 34:513–517CrossRef
96.
Chun GT, Agathos SN (1993) Dynamic response of immobilized cells to pulse addition of l-valine in cyclosporin ‘A’ biosynthesis. J Biotechnol 27(3):283–294CrossRef
97.
Agathos SN, Lee J (1993) Mathematical modeling of the production of cyclosporin ‘A’ by Tolypocladium inflatum: effect of l-valine. Biotechnol Prog 9(1):54–63CrossRef
98.
Balakrishnan K, Pandey A (1996) Growth and cyclosporin a production by an indigenously isolated strain of Tolypocladium inflatum. Folia Microbiol 41:401–406CrossRef
99.
Balaraman K, Mathew N (2006) Optimization of media composition for the production of cyclosporin A by Tolypocladium species. Indian J Med Res 123:525–530
100.
Kannan ND, Kalaichelvan PT (2007) Production of immunosuppressant drug cyclosporin ‘A’ from Tolypocladium inflatum in presence of l-valine. Allelopathy J 19(2):0971–4693
101.
Margaritis A, Ly M (2007) Effect of temperature on the extraction kinetics and diffusivity of cyclosporin A in the fungus Tolypocladium inflatum. Biotechnol Bioeng 96(5):945–955CrossRef
102.
Survase SA, Shaligram NS, Pansuriya RC, Annapure US, Singhal RS (2008) A novel medium for the enhanced production of cyclosporin ‘A’ by Tolypocladium inflatum MTCC 557 using solid state fermentation. J Microbiol Biotechnol 19(2):805–824
103.
Nisha AK, Meignanalakshmi K, Ramasamy K (2008) Comparative effect of amino acids in the production of cyclosporin by solid and submerged fermentation. Biotechnology 7(2):205–208CrossRef
104.
Tanseer S, Anjum T (2011) Modification of c and n sources for enhanced production of cyclosporin ‘a’ by Aspergillus terreus. Braz J Microbiol 42(4):1374–1383CrossRef
105.
Azam A, Anjum T, Iram W (2012) Trichoderma harzianum: a new fungal source for the production of cyclosporin ‘A’. Bangladesh J Pharmacol 7(1):33–35CrossRef
106.
Anjum T, Azam A, Iram W (2012) Production of cyclosporin ‘A’ by submerged fermentation from a local isolate of Penicillium fellutanum. Indian J Pharm Sci 74(4):372–374CrossRef
107.
Foster BC, Coutts RT, Pasutto FM, Dossetor JB (1983) Production of cyclosporin ‘A’ by carrageenan-immobilized Tolypocladium inflatum in an airlift reactor with external loop. Biotechnol Lett 5(10):693–696CrossRef
108.
Chun GT, Agathos SN (1991) Comparative studies of physiological and environmental effects on the production of cyclosporin ‘A’ in suspended and immobilized cells of Tolypocladium inflatum. Biotechnol Bioeng 37:256–265CrossRef
109.
Lee TH, Chun GT, Chang YK (1997) Development of sporulation/immobilization method and its application for the continuous production of cyclosporin ‘A’ by Tolypocladium inflatum. Biotechnol Prog 13:546–550CrossRef
110.
Sallam LAR, El-Refai AH, Hamdi AA, El-Minofi AH, Abd-Elsalam SI (2005) Studies on the application of immobilization technique for the production of cyclosporin ‘A’ by a local strain of Aspergillus terreus. J Gen Appl Microbiol 51(03):143–149CrossRef
111.
Tempest DR, Neijssel OM, Zenenboom W (1983) Properties and performances of microorganism in laboratory culture. Their relevance to growth in natural ecosystems. In: Slater JH, Whillenbary R, Wimpenny JW (eds) Microbes in their natural environment. General microbiology. Symposium no 34. Cambridge University Press, England. pp 119–152
112.
Richard CG, Bhattacharjee JK (1992) Lysine biosynthesis in selected pathogenic fungi. Characterization of lysine auxotrophs and the cloned LYSI gene of Candida albican. J Bacteriol 174:7379–7384CrossRef
113.
Fleming HP, Kyung KH, Breidt F (1995) Vegetable fermentations. In: Rehm HJ, Reed G (eds) Biotechnology. Enzyme, biomass, food and feed, vol 9. VCH Verlag, Weinheim, Germany. pp 629–661CrossRef
114.
Vinci VA, Hoerner TD, Coffman AD, Schimmel TG, Dabora RL, Kirpekar AC, Ruby CL, Stieber RW (1991) Mutants of a lovastatin-hyperproducing Aspergillus terreus deficient in the production of sulochrin. J Ind Microbiol 8:113–120CrossRef
115.
Rowlands RT (1983) Industrial fungal genetics and strain selection. In: Smith JE, Berry DR, Kristiansen B (eds) The filamentous fungi, vol 4. pp 346–372
116.
Rowlands RT, Normansell IO (1983) Current strategies in industrial strain selection. In: Nisbet LJ, Winstanley DJ (eds) Bioactive microbial products. Development and production. Academic Press, London. pp 1–18
117.
Rowlands RT (1992) Strain improvement and strain stability. In: Finkelstein DB, Ball C (eds) Biotechnology of filamentous fungi: technology and products. Butterworth-Heinemann, Boston, pp 41–64CrossRef
118.
Calam CT (1964) The selection, improvement, and preservation of microorganisms. Prog Ind Microbiol 5:1–53
119.
Davies OL (1964) Screening for improved mutants in antibiotic research. Biometrics 20:576–591CrossRef
120.
Calam CT (1970) lmprovement of micro-organisms by mutation, hybridization and selection. Methods Microbiol 3:435–459CrossRef
121.
Queener SW, Lively DH (1986) Screening and selection for strain Improvement. In: Demain AL, Solomon NA (eds) Manual of industrial microbiology and biotechnology. American Society of Microbiology, Washington, DC. pp 155–169
122.
Chang LT, Elander RP (1979) Rational selection for improved cephalosporin C productivity in strains of Acremonium chvsogenum Gams. Dev Ind Microbiol 20:367–379
123.
Swidinsky K (1998) Regulation of secondary metabolism from Tolypocladium inflatum: a study on strain improvement in cyclosporin A productivity and its relation to growth and glucose metabolism. National Library of Canada, Winnipeg, Manitoba. pp 1–29
124.
Ramana Murthy MV, Mohan EVS, Sadhukhan AK (1999) Cyclosporin A production by Tolypocladium inflatum using solid-state fermentation. Process Biochem 34:269–280CrossRef
125.
Lanhart K, Hejtmanek M, Kunert J (1961) Biochemical mutants of Microsporum gypseum. Acta Univ Olmuc Fact Med 63:115–130
126.
Stelow RB, Carrier WL (1966) Pyrimidine dimers in ultraviolet irradiated DNA’s. J Mol Biol 17:237CrossRef
127.
128.
Gharavi M, Najafi RB, Kloobandi A (2004) Mutation of Tolypocladium inflatum (dsm 915) by UV radiation for higher production of cyclosporin A. Saudi Pharm J 12:2–3
129.
Lee MJ, Duong CTP, Han K, Eung-Soo K (2009) Combination strategy to increase cyclosporin A productivity by Tolypocladium niveum using random mutagenesis and protoplast transformation. J Microbiol Biotechnol 19(9):869–872CrossRef
130.
Iram W, Anjum T (2012) Production enhancement of cyclosporin ‘A’ by Aspergillus terreus through mutation. Afr J Biotechnol 11(7):1736–1743
131.
Agathos SN, Parekh R (1990) Enhancement of cyclosporin production in a Tolypocladium inflatum strain after epichlorohydrin treatment. J Biotechnol 13(1):73–81CrossRef
132.
Simpson IN, Caten CE (1979) Induced quantitative variation for penicillin titre in clonal populations of Aspergillus nidulans. J Gen Microbiol 110:1–12CrossRef
133.
Ibrahim SA, Abd-Elnasser, Kattab A (2009) Enhancement of cyclosporin a production by Tolypocladium inflatum using some mutagenic agents. Acta Pharm Sci 51(1):87–92
134.
Derk B (1990) Supercritical carbon dioxide extraction of cyclosporine from the fungus Beauvaria nivea. Digitized Theses. Paper 1907
135.
Survase SA, Annapure US, Singhal RS (2009) Statistical optimization for improved production of cyclosporin A in solid-state fermentation. J Microbiol Biotechnol 19(11):1385–1392
136.
Szanya T, Hanak L, Strbka G, Nagy E, Melczer I, Deak G et al (1995) Process for the purification of cyclosporin A. US Patent 5,382,655
137.
Ly M, Margaritis A, Jajuee B (2007) Effect of solvent concentration on the extraction kinetics and diffusivity of cyclosporin A in the fungus Tolypocladium inflatum. Biotechnol Bioeng 96(1):67–79CrossRef
138.
Tredger JM, Roberts N, Sherwood R, Higgins G, Keating J (2000) Comparison of five cyclosporin immunoassays with HPLC. Clin Chem Lab Med 38(11):1205–1207CrossRef
139.
Kreuzig F (1984) High-speed liquid chromatography with conventional instruments for the determination of cyclosporin A, B, C and D in fermentation broth. J Chromatogr 290:181–186CrossRef
140.
Simpson J, Zhang Q, Ozaeta P, Aboleneen H (1998) A specific method for the measurement of cyclosporin A in human whole blood by liquid chromatography-tandem mass spectrometry. Ther Drug Monit 20:294–300CrossRef
141.
Salm P, Taylor PJ, Lynch SV, Warnholtz CR, Pillans PI (2005) A rapid HPLC-mass spectrometry cyclosporin method suitable for current monitoring practices. Clin Biochem 38(7):667–673CrossRef
142.
George N, Kuppusamy M, Balaraman K (1992) Optimization of high performance liquid chromatographic conditions for the determination of cyclosporins A, B and C in fermentation samples. J Chromatogr 604:285–289CrossRef
143.
Husek A (1997) High performance liquid chromatographic analysis of cyclosporin A and its oral solutions. J Chromatogr A 759(1–2):217–224CrossRef
Metadata
Title
Production of Cyclosporine A by Submerged Fermentation
Authors
Tehmina Anjum
Wajiha Iram
Copyright Year
2017
Book
Fungal Metabolites

Print ISBN: 978-3-319-25000-7

Electronic ISBN: 978-3-319-25001-4

Copyright Year: 2017

DOI
https://doi.org/10.1007/978-3-319-25001-4_4